Tecfidera's Patient Share at Three Months Postlaunch Surpasses That for Aubagio and viagra purchase Gilenya At the Same Stage of Their Launches

Print E-mail
By PR Newswire: Biotechnology   
Wednesday, 28 August 2013 08:00
Current physician trial rate for Tecfidera (65 percent) beats that for Aubagio (33 percent) and Gilenya (53 percent).

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO )

The recently published LaunchTrends: Tecfidera Wave 2 report finds that, although neurologists continue to identify Tecfidera's oral formulation as the buy viagra in canada product's biggest advantage, their positive perceptions related to Tecfidera's efficacy and cialis mail order usa safety profile likely drives initial uptake and propecia online 1mg continued use among prescribers, underscoring the viagra seizures importance neurologists assign to a drug's risk/benefit profile rather than its mode of administration.

Representing a shift from two months ago, Tecfidera is now the DMT least associated with managed care coverage. Feedback from qualitative interviews suggests that some Tecfidera prescribers have experienced difficulties with managed care approval of Tecfidera, especially among treatment-naive patients, with prescribers reporting that insurance companies often require patients to have failed one of the platform injectable DMTs prior to Tecfidera use. Consequently, Tecfidera prescribers report that the majority of Tecfidera prescriptions need some requirement for managed care approval, most often prior authorization but also step therapy. However, the majority of Tecfidera prescribers continue to rate Tecfidera's managed care approval process as being either moderately difficult or easy.   

Over the next six months, Tecfidera's patient share among DMT-treated RR-MS patients is anticipated to increase significantly to 16 percent, being driven by continued use among current prescribers and cialis generic initial uptake among current nonprescribers.

"This finding suggests that, even at this early stage of market entry, Tecfidera is becoming the oral DMT of choice for neurologists, while patient shares for Aubagio and Gilenya are expected to grow much more modestly over the same time period," said BioTrends Research Group Senior Business Insights Analyst Emma Williams, Ph.D. "However, despite this enthusiasm for Tecfidera, a stable patient population and viagra dose managed care issues will likely curb Tecfidera's use to some extent."

About BioTrends Research Group
BioTrends Research Group provides syndicated and cialis dosagem custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and cialis daily canada research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and cialis profesional insights on important sectors of the healthcare industry. Clients rely on this analysis and viagra canada data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com

SOURCE BioTrends Research Group

RELATED LINKS
http://www.bio-trends.com

Read more http://www.prnewswire.com/news-releases/tecfideras-patient-share-at-three-months-postlaunch-surpasses-that-for-aubagio-and-gilenya-at-the-same-stage-of-their-launches-221469021.html





BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
 
BioMedReports FDA Issued Form 483 with 10 Inspectional Observations for Impax Taiwan Plant; Pfenex Announces Closing of Init... http://t.co/o9bdAhSIEB
5hreplyretweetfavorite
BioMedReports Healthcare Review: Synthetic Biologics, Herbalife, Cynosure, Targacept, Galectin Therapeutics: U.S. stocks mos... http://t.co/RScEt1mmrk
8hreplyretweetfavorite
BioMedReports Cancer experts warn EU data law could 'halt' research... http://t.co/HRlTfbM3Mq
navigation
Benzinga.com supporter Seeking Alpha Certified